Mechanisms of PARP Inhibitor Resistance and Potential Therapeutic Strategies in Breast Cancer

Breast cancer constitutes one of the most commonly diagnosed malignancies among the female population globally, and its development and progression are intimately connected with functional anomalies in the DNA damage response (DDR) pathway. A synthetic lethality basis for the clinical use of poly (ADP-ribose) polymerase inhibitors (PARPi) is provided by homologous recombination deficiency (HRD). Several PARPi, such as olaparib and talazoparib, are approved as monotherapies for specific populations of patients with germline BRCA-mutated, HER2-negative breast cancer. They exert considerable efficacy by blocking PARP catalytic activity, interfering with liquid–liquid phase separation, and causing PARP-DNA entrapment. Nevertheless, sustained therapeutic benefits from PARPi are markedly diminished once acquired resistance develops. The underlying resistance mechanisms, which include BRCA1/2 reversion mutations, upregulation of the homologous recombination (HR) pathway, replication fork stabilization, clearance of trapped PARP1, and increased drug efflux, are intricate and varied. In recent years, combination therapy strategies have received considerable attention, as they can overcome treatment resistance and increase the number of patients benefiting from treatment. Preclinical and early-phase clinical studies have revealed synergistic interactions of PARPi with DNA-damaging agents, immune checkpoint inhibitors, cell cycle checkpoint inhibitors, and radiotherapy. Meanwhile, the discovery of prospective targets such as SCRN2, FGFR, and USP37 opens fresh options for reversing resistance. In order to optimize clinical treatment regimens and improve patient prognosis, this study will methodically explain the mechanism of action, resistance routes, and intervention techniques of PARPi in breast cancer.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-17
DOI
https://doi.org/10.3390/ijms272210331
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mechanisms of PARP Inhibitor Resistance and Potential Therapeutic Strategies in Breast Cancer

Ziqiang Zhu, Xiaotao Qian, Jinfeng Liu, Chengqian Zhou
2 links
International Journal of Molecular Sciences
PARP inhibition in cancer therapy
article

Mechanisms of PARP Inhibitor Resistance and Potential Therapeutic Strategies in Breast Cancer

Ziqiang Zhu, Xiaotao Qian, Jinfeng Liu, Chengqian Zhou
article en

Abstract

Breast cancer constitutes one of the most commonly diagnosed malignancies among the female population globally, and its development and progression are intimately connected with functional anomalies in the DNA damage response (DDR) pathway. A synthetic lethality basis for the clinical use of poly (ADP-ribose) polymerase inhibitors (PARPi) is provided by homologous recombination deficiency (HRD). Several PARPi, such as olaparib and talazoparib, are approved as monotherapies for specific populations of patients with germline BRCA-mutated, HER2-negative breast cancer. They exert considerable efficacy by blocking PARP catalytic activity, interfering with liquid–liquid phase separation, and causing PARP-DNA entrapment. Nevertheless, sustained therapeutic benefits from PARPi are markedly diminished once acquired resistance develops. The underlying resistance mechanisms, which include BRCA1/2 reversion mutations, upregulation of the homologous recombination (HR) pathway, replication fork stabilization, clearance of trapped PARP1, and increased drug efflux, are intricate and varied. In recent years, combination therapy strategies have received considerable attention, as they can overcome treatment resistance and increase the number of patients benefiting from treatment. Preclinical and early-phase clinical studies have revealed synergistic interactions of PARPi with DNA-damaging agents, immune checkpoint inhibitors, cell cycle checkpoint inhibitors, and radiotherapy. Meanwhile, the discovery of prospective targets such as SCRN2, FGFR, and USP37 opens fresh options for reversing resistance. In order to optimize clinical treatment regimens and improve patient prognosis, this study will methodically explain the mechanism of action, resistance routes, and intervention techniques of PARPi in breast cancer.

International Journal of Molecular SciencesVol. 27(22)
Nanjing University of Chinese Medicine (CN), Chinese Academy of Sciences (CN), Hefei Institutes of Physical Science (CN), Cancer Hospital of Chinese Academy of Medical Sciences (CN)
Good health and well-being
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon